Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 1/20 | 0.51 |
| ▸ | THRB | P10828 | 4/20 | 0.44 |
| ▸ | THRA | P10827 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | ELANE | P08246 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.39 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9486380 | 0.98 | F2 (0.49) | F2THRBTHRAKMT2AHTT | |
| SCHEMBL9488379 | 0.98 | F2 (0.49) | F2THRBTHRAKMT2AHTT | |
| SCHEMBL9486941 | 0.98 | F2 (0.49) | F2THRBTHRAKMT2AHTT | |
| SCHEMBL9487871 | 0.98 | F2 (0.49) | F2THRBTHRAKMT2AHTT | |
| SCHEMBL11405959 | 0.95 | F2 (0.51) | F2THRBTHRAKMT2AHTT | |
| SCHEMBL11412043 | 0.95 | F2 (0.51) | F2THRBTHRAKMT2AHTT | |
| SCHEMBL11412150 | 0.95 | F2 (0.51) | F2THRBTHRAKMT2AHTT | |
| SCHEMBL9319339 | 0.95 | F2 (0.53) | F2THRBTHRAKMT2AHTT | |
| SCHEMBL9487767 | 0.94 | F2 (0.50) | F2THRBTHRAKMT2AHTT | |
| SCHEMBL9485858 | 0.94 | F2 (0.50) | F2THRBTHRAKMT2AHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9933679-B2 | Birefringence improving agent, ferroelectric liquid crystal composition and liquid crystal display device using the agent, and compound | LC VISION, LLC (US) | 2018-04-03 | — | — | US | disclosed |
| US-20160161817-A1 | BIREFRINGENCE IMPROVING AGENT, FERROELECTRIC LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE USING THE AGENT, AND COMPOUND | LC VISION, LLC | 2016-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160161817-A1 | BIREFRINGENCE IMPROVING AGENT, FERROELECTRIC LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE USING THE AGENT, AND COMPOUND | PYCARD, BIRC7, BIRC8 | F2 2263/4885THRB 4832/4885THRA 4571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.